Jinghua Pharmaceutical Group Co., Ltd. (SHE:002349)

China flag China · Delayed Price · Currency is CNY
7.16
-0.05 (-0.69%)
May 20, 2026, 1:35 PM CST
Market Cap5.98B +5.2%
Revenue (ttm)1.48B +5.6%
Net Income222.94M +9.4%
EPS0.27 +8.7%
Shares Out828.87M
PE Ratio26.51
Forward PEn/a
Dividend0.09 (1.26%)
Ex-Dividend DateJun 6, 2025
Volume5,551,500
Average Volume14,067,538
Open7.20
Previous Close7.21
Day's Range7.11 - 7.20
52-Week Range6.72 - 8.45
Beta0.17
RSI43.47
Earnings DateApr 23, 2026

About SHE:002349

Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Flucytosine, Piroxicam, and Propylthiouracil APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. The company was founded in 1957 and is based in Nantong, China. [Read more]

Sector Healthcare
Founded 1957
Employees 1,490
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002349
Full Company Profile

Financial Performance

In 2025, SHE:002349's revenue was 1.46 billion, an increase of 4.13% compared to the previous year's 1.40 billion. Earnings were 219.28 million, an increase of 3.12%.

Financial Statements